<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00471185</url>
  </required_header>
  <id_info>
    <org_study_id>31511-W</org_study_id>
    <secondary_id>07-4947-W 02</secondary_id>
    <nct_id>NCT00471185</nct_id>
  </id_info>
  <brief_title>ACY-6 Oral Administration of Acyline</brief_title>
  <acronym>ACY-6</acronym>
  <official_title>Oral Administration of the GnRH Antagonist Acyline in Normal Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merrion Pharmaceuticals, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, we propose oral dosing of GIPET enhanced oral acyline (MER-104) to determine
      if this potentially useful compound is safe and effective at suppression of gonadotropins
      after oral dosing in man.

      Hypothesis: A single dose of Acyline will suppress gonadotropins, and testosterone, estradiol
      and dihydrotestosterone (DHT) for 24 hours in man, and the magnitude and duration of the
      suppression will increase with increasing doses of Acyline.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to test how the body responds to a new oral form of acyline and
      to also look at the safety of oral acyline.

      Acyline temporarily blocks the production of the hormone testosterone in normal men. It has
      been given to over 100 men in an injection form. This study will be testing acyline in a pill
      form. This is the first time the pill form has been tested in humans.

      This study may help develop an oral form of a testosterone-blocker, which may be useful in
      the treatment of diseases such as prostate cancer, premature puberty and possibly in a male
      contraceptive.

      This study requires three 12-hour blood draw periods for pharmacokinetics (PK) testing. PK
      testing looks to see how much study drug is in the blood. This gives information about how
      the body handles and gets rid of the study drug.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the suppressive effects of GIPET-enhanced oral Acyline on pituitary gonadotropin and testosterone secretion in normal men and to assess any potential side effects of GIPET enhanced oral Acyline</measure>
    <time_frame>28-days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To define the pharmacokinetics of GIPET enhanced oral Acyline</measure>
    <time_frame>28-days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess any potential side effects of GIPET enhanced oral Acyline</measure>
    <time_frame>28-days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive progressively increasing doses of 10, 20 and 40 mg of oral acyline, on 3 occasions, each separated by 1 week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acyline</intervention_name>
    <description>10, 20 and 40 mg of Oral acyline, given on 3 occasions, separated by 1 week.</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males between 18-50 years of Age in good health

        Exclusion Criteria:

          -  Men in poor health, significant chronic or acute medical illness, known history of
             alcohol, illicit drug or anabolic steroid abuse
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John K Amory</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://depts.washington.edu/popctr/</url>
  </link>
  <reference>
    <citation>Herbst KL, Anawalt BD, Amory JK, Bremner WJ. Acyline: the first study in humans of a potent, new gonadotropin-releasing hormone antagonist. J Clin Endocrinol Metab. 2002 Jul;87(7):3215-20.</citation>
    <PMID>12107227</PMID>
  </reference>
  <reference>
    <citation>Herbst KL, Coviello AD, Page S, Amory JK, Anawalt BD, Bremner WJ. A single dose of the potent gonadotropin-releasing hormone antagonist acyline suppresses gonadotropins and testosterone for 2 weeks in healthy young men. J Clin Endocrinol Metab. 2004 Dec;89(12):5959-65.</citation>
    <PMID>15579744</PMID>
  </reference>
  <reference>
    <citation>Matthiesson KL, Amory JK, Berger R, Ugoni A, McLachlan RI, Bremner WJ. Novel male hormonal contraceptive combinations: the hormonal and spermatogenic effects of testosterone and levonorgestrel combined with a 5alpha-reductase inhibitor or gonadotropin-releasing hormone antagonist. J Clin Endocrinol Metab. 2005 Jan;90(1):91-7. Epub 2004 Oct 27.</citation>
    <PMID>15509637</PMID>
  </reference>
  <reference>
    <citation>Amory JK, Bremner WJ. Oral testosterone in oil plus dutasteride in men: a pharmacokinetic study. J Clin Endocrinol Metab. 2005 May;90(5):2610-7. Epub 2005 Feb 15.</citation>
    <PMID>15713724</PMID>
  </reference>
  <reference>
    <citation>Amory JK, Page ST, Bremner WJ. Oral testosterone in oil: pharmacokinetic effects of 5alpha reduction by finasteride or dutasteride and food intake in men. J Androl. 2006 Jan-Feb;27(1):72-8.</citation>
    <PMID>16400081</PMID>
  </reference>
  <reference>
    <citation>Page ST, Lin DW, Mostaghel EA, Hess DL, True LD, Amory JK, Nelson PS, Matsumoto AM, Bremner WJ. Persistent intraprostatic androgen concentrations after medical castration in healthy men. J Clin Endocrinol Metab. 2006 Oct;91(10):3850-6. Epub 2006 Aug 1.</citation>
    <PMID>16882745</PMID>
  </reference>
  <reference>
    <citation>Page ST, Amory JK, Anawalt BD, Irwig MS, Brockenbrough AT, Matsumoto AM, Bremner WJ. Testosterone gel combined with depomedroxyprogesterone acetate is an effective male hormonal contraceptive regimen and is not enhanced by the addition of a GnRH antagonist. J Clin Endocrinol Metab. 2006 Nov;91(11):4374-80. Epub 2006 Aug 29.</citation>
    <PMID>16940442</PMID>
  </reference>
  <results_reference>
    <citation>Snyder CN, Clark RV, Caricofe RB, Bush MA, Roth MY, Page ST, Bremner WJ, Amory JK. Pharmacokinetics of 2 novel formulations of modified-release oral testosterone alone and with finasteride in normal men with experimental hypogonadism. J Androl. 2010 Nov-Dec;31(6):527-35. doi: 10.2164/jandrol.109.009746. Epub 2010 Apr 8.</citation>
    <PMID>20378927</PMID>
  </results_reference>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 7, 2007</study_first_submitted>
  <study_first_submitted_qc>May 8, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2007</study_first_posted>
  <last_update_submitted>December 2, 2010</last_update_submitted>
  <last_update_submitted_qc>December 2, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2010</last_update_posted>
  <responsible_party>
    <name_title>John K Amory, MD, MPH</name_title>
    <organization>University of Washington</organization>
  </responsible_party>
  <keyword>Male Contraception</keyword>
  <keyword>Acyline</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

